EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Global spatiotemporal dynamics of Mycoplasma pneumoniae re-emergence after COVID-19 pandemic restrictions: an epidemiological and transmission modelling study

ESGMAC MAPS study group

The Lancet Microbe · 2025-04 · 6 (4) · 101019

DOI: 10.1016/j.lanmic.2024.101019 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Lancet Microbe, 2025-04. Verfasst von ESGMAC MAPS study group. Hauptthemen laut MEDLINE: COVID-19, Pneumonia, Mycoplasma, Mycoplasma pneumoniae. Die Arbeit wurde bisher 73-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Mycoplasma pneumoniae is a major cause of respiratory tract infections. We aimed to investigate the spatiotemporal dynamics, antimicrobial resistance, and severity of the delayed re-emergence of infections with M pneumoniae after the implementation of non-pharmaceutical interventions (NPIs) against COVID-19. METHODS: Epidemiological data (positive and total test numbers, and macrolide-resistant M pneumoniae detections) and clinical data (hospitalisations, intensive care unit [ICU] admissions, and deaths) were collected through our global surveillance from April 1, 2017 to March 31, 2024. The moving epidemic method (MEM) was used to establish epidemic periods, and the time-series susceptible-infected-recovered (TSIR) model to investigate the delayed re-emergence. FINDINGS: The dataset included 65 sites in 29 countries from four UN regions: Europe, Asia, the Americas, and Oceania. A global re-emergence of M pneumoniae cases by PCR detection was noted from the second half of 2023. The mean global detection rate was 11·47% (SD 15·82) during the re-emergence (April, 2023-March, 2024). By use of MEM, the re-emergence was identified as epidemic in all four UN regions, simultaneously in ten countries at calendar week 40 (early October, 2023). Macrolide-resistant M pneumoniae rates from Europe and Asia were 2·02% and 71·22%, respectively, and did not differ between the re-emergence and pre-COVID-19 pandemic periods. During the re-emergence, some countries reported increased hospitalisations (in adults, two of ten countries; and in children, two of 14 countries) and ICU admissions (in adults, one of nine countries; and in children, two of 14 countries). Overall, 65 (0·11%) deaths were reported, without statistical difference between pre-COVID-19 pandemic and re-emergence. The TSIR model accurately predicted, considering a 3-week generation time of M pneumoniae and a 90% reduction in transmission through NPIs, the observed delayed re-emergence. INTERPRETATION: This large global dataset for M pneumoniae detections shows that although there was an unprecedented high number of detections across many countries in late 2023, the severity and number of deaths remained low. Our results suggest that the delayed re-emergence was related to the long incubation period of M pneumoniae infection. FUNDING: None.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Pneumonia, MycoplasmaMycoplasma pneumoniaeHumansSARS-CoV-2PandemicsGlobal HealthAnti-Bacterial AgentsSpatio-Temporal AnalysisAdultDrug Resistance, BacterialChildEpidemiological ModelsMacrolides

Substanzen

Anti-Bacterial AgentsMacrolides

Zitieren

APA

ESGMAC MAPS study group (2025). Global spatiotemporal dynamics of Mycoplasma pneumoniae re-emergence after COVID-19 pandemic restrictions: an epidemiological and transmission modelling study. The Lancet Microbe, 6(4), 101019. https://doi.org/10.1016/j.lanmic.2024.101019

Vancouver

ESGMAC MAPS study group. Global spatiotemporal dynamics of Mycoplasma pneumoniae re-emergence after COVID-19 pandemic restrictions: an epidemiological and transmission modelling study. The Lancet Microbe. 2025;6(4):101019. doi:10.1016/j.lanmic.2024.101019

BibTeX
@article{ESGMACMAPSstudygroup2025,
  author = {ESGMAC MAPS study group, ESGMAC MAPS study group},
  title = {Global spatiotemporal dynamics of Mycoplasma pneumoniae re-emergence after COVID-19 pandemic restrictions: an epidemiological and transmission modelling study},
  journal = {The Lancet Microbe},
  year = {2025},
  volume = {6},
  number = {4},
  pages = {101019},
  doi = {10.1016/j.lanmic.2024.101019}
}
Kostenlos starten →